Analyst Reco. Clene Inc.

Equities

CLNN

US1856341029

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-03 EDT			5-day change	1st Jan Change
0.4349 ^USD	-0.41%		+27.95%	+46.63%

04-16	Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	CI
03-15	Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Benchmark Cuts Price Target on Clene to $5 From $7, Maintains Buy Rating	23-06-30	MT
HC Wainwright Cuts Price Target on Clene to $7 From $15, Keeps Buy Rating	23-06-21	MT
EF Hutton Adjusts Clene Price Target to $10 From $13, Maintains Buy Rating	23-06-20	MT
Cantor Fitzgerald Adjusts Price Target on Clene to $4 From $5, Maintains Overweight Rating	23-05-16	MT
Benchmark Adjusts Price Target on Clene to $7 From $11, Keeps Buy Rating	23-04-10	MT
Cantor Fitzgerald Adjusts Price Target on Clene to $8 From $6, Maintains Buy Rating	23-03-10	MT
EF Hutton Starts Clene at Buy With $13 Price Target	23-03-08	MT
Oppenheimer Downgrades Clene to Perform From Outperform, Removes $17 Price Target	22-10-04	MT
Canaccord Genuity Adjusts Clene's Price Target to $6 From $10, Reiterates Buy Rating	22-10-04	MT
Benchmark Adjusts Clene's Price Target to $11 From $25, Reiterates Buy Rating	22-10-04	MT
Oppenheimer Adjusts Clene's Price Target to $17 From $16, Maintains Outperform Rating	22-08-17	MT
Cantor Fitzgerald Adjusts Clene Price Target to $12 From $10, Maintains Overweight Rating	22-08-16	MT
HC Wainwright Initiates Clene at Buy With $16 Price Target	22-07-18	MT
Clene Reports Decreased Mortality Rates in RESCUE-ALS Trial	22-07-14	MT
Canaccord Genuity Starts Clene at Buy With $10 Price Target	22-05-02	MT
Oppenheimer Adjusts Clene's Price Target to $19 From $20, Maintains Outperform Rating	22-02-15	MT
Cantor Fitzgerald Adjusts Clene's Price Target to $15 From $24, Reiterates Overweight Rating	21-11-03	MT
CLENE : Oppenheimer Initiates Coverage on Clene With Outperform Rating, $20 Price Target	21-09-28	MT
CLENE : Maxim Group Starts Clene at Buy With $18 Price Target	21-05-20	MT
CLENE : Cantor Fitzgerald Starts Clene at Overweight With $22 Price Target	21-05-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Clene Inc.

Equities

CLNN

US1856341029

Analyst Reco.

Filters